Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

Publisher： Karger

E-ISSN： 1423-0232|71|5-6|320-326

ISSN： 0030-2414

Source： Oncology, Vol.71, Iss.5-6, 2007-09, pp. : 320-326

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evidence-based chemotherapeutic management of potentially platinum-sensitive recurrent ovarian cancer

By Markman Maurie  

Therapy, Vol. 7, Iss. 3, 2010-05 ,pp. : 269-275

Future Medicine

Access to resources Recommend Favorite

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-05 ,pp. : 433-437

Karger

Access to resources Recommend Favorite

Haematological Evaluation of Weekly Therapy with Topotecan for the Treatment of Recurrent Ovarian Cancer Resistant to Platinum-Based Therapy

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 177-184

Karger

Access to resources Recommend Favorite

Topotecan and Gemcitabine in Platinum/Paclitaxel-Resistant Ovarian Cancer

By  

Oncology, Vol. 60, Iss. 1, 2000-12 ,pp. : 19-23

Karger

Access to resources Recommend Favorite

Dose Finding Study for Combination Treatment with Topotecan and Gemcitabine of Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum

By  

Oncology Research and Treatment, Vol. 27, Iss. 1, 2004-03 ,pp. : 58-64

Karger

Access to resources Recommend Favorite